When normal heart rhythms are not restored quickly, sudden cardiac arrest can cause death.
L’Agenzia Italiana del Farmaco, in accordo con l’Agenzia Europea dei
Medicinali, rende disponibili nuove e importanti informazioni sull'ampliamento delle avvertenze circa il rischio di eventi vascolari occlusivi associato a ponatinib.
Sample from one lot of Hydravax revealed the presence of a diuretic. Possible effects of using a diuretic include an electrolyte imbalance due to water loss.
Falsely low blood glucose results can lead patients to try to raise their blood glucose when it is
unnecessary, or to fail to treat elevated blood glucose due to a falsely low reading.
Voluntary recall of one lot due to particulate matter found in one vial. If infused, particulate matter could lead to potential venous and/or arterial thromboembolism.
Potential for a large leak from the absorber circuit while operating in bag mode and could impede the ability to provide ventilation in bag mode.
Clinical consequences associated with use of the contaminated and/or adulterated products may include intraocular infection, inflammation and elevated intraocular pressure.
Health care professionals, pharmacies, and patients will no longer be required to enroll in the rosiglitazone REMS program to be able to prescribe, dispense, or receive rosiglitazone medicines.
May result in a delay, interruption or over-infusion in therapy, which have a worst case potential to result in significant injury or death depending on the drug and the dosage administered.
80.211.154.110